Elsevier

Journal of Psychiatric Research

Volume 47, Issue 9, September 2013, Pages 1247-1253
Journal of Psychiatric Research

Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects

https://doi.org/10.1016/j.jpsychires.2013.05.001Get rights and content

Abstract

Neurochemical studies have pointed to a modulatory role in human aggression for various central neurotransmitters. Some (e.g., serotonin) appear to play an inhibitory role, while others appear to play a facilitator role. While recent animal studies of glutaminergic activity suggest a facilitator role for central glutamate in the modulation of aggression, no human studies of central glutaminergic indices have yet been reported regarding aggression. Basal lumbar cerebrospinal fluid (CSF) was obtained from 38 physically healthy subjects with DSM-IV Personality Disorder (PD: n = 28) and from Healthy Volunteers (HV: n = 10) and assayed for glutamate, and other neurotransmitters, in CSF and correlated with measures of aggression and impulsivity. CSF Glutamate levels did not differ between the PD and HC subjects but did directly correlate with composite measures of both aggression and impulsivity and a composite measure of impulsive aggression in both groups. These data suggest a positive relationship between CSF Glutamate levels and measures of impulsive aggression in human subjects. Thus, glutamate function may contribute to the complex central neuromodulation of impulsive aggression in human subjects.

Introduction

Glutamate is the most abundant excitatory neurotransmitter in the vertebrate nervous system (Niciu et al., 2012). Glutamate is stored in vesicles at chemical synapses where nerve impulses trigger release of glutamate from the pre-synaptic neuron onto post-synaptic glutamate receptors such as the ionotropic NMDA and AMPA/Kainate receptors and the G-protein coupled metabotropic glutamate receptors. Glutamate plays an important role in brain synaptic plasticity and is involved in a number of cognitive functions including learning and memory in the hippocampus, neocortex, and other brain regions.

Glutamate has been implicated to play a role in a variety of neuropsychiatric disorders including schizophrenia (Lin et al., 2012), mood disorder (Machado-Vieira et al., 2012), anxiety disorders (Riaza Bermudo-Soriano et al., 2012), addictive disorders (Olive et al., 2012), and other neuropsychiatric disorders (e.g., Hu et al., 2012; Carlson, 2012). While little work has been reported on the role of glutamate in human aggressive behavior, preclinical studies suggest that stimulation of central glutamate receptors typically increases aggressive behavior in lower mammals.

As demonstrated in a number of preclinical studies in rodents, an excitatory amino acid pathway from the medial hypothalamus (MH) to the periaqueductal gray (PAG) is associated with aggressive behavior (Beart et al., 1998, 1990; Beitz, 1989). In the rat, there is a dense and distinct group of glutamatergic neurons expressing glutamate transporter protein over the entire hypothalamic attack area, with the rostral portion predominantly containing glutamatergic, and the caudal portion having both glutaminergic and, to a lesser degree, GABAergic, neurons (Hrabovszky et al., 2005). Microinjections of glutamate into the cat PAG elicit defensive rage (Bandler, 1984), a finding consistent with the release of glutamate by MH neurons and the activation of PAG neurons in the expression of defensive rage in the cat. This was confirmed in subsequent studies demonstrating that pretreatment with the glutamate antagonist kynurenic acid blocked MH facilitation of PAG elicited defensive rage, and that NMDA injected into PAG defensive rage sites facilitated the rage response elicited from that site (Lu et al., 1992). Administration of an NMDA receptor antagonist into the PAG blocked MH facilitation of PAG-elicited defensive rage. The antagonist dose-dependently suppressed defensive rage elicited by stimulation of the MH (Schubert et al., 1996). This study also reported that a considerable number of glutamate neurons within the anteromedial hypothalamus project to PAG defensive rage sites (Schubert et al., 1996).

Excitatory inputs from the basal amygdala also project to the PAG and there is evidence for PAG NMDA receptor mediated defensive rage following their stimulation (Shaikh et al., 1994); basal amygdaloid neurons projecting to PAG defensive rage sites also stain immunopositive for glutamate. In addition, mice bred for reduction of function in the NMDA R1 subunit display an absence of species-typical fighting in the resident intruder model of aggression (Duncan et al., 2004).

Preclinical studies of the other ionotropic glutamate receptor, AMPA, and as well as metabotropic glutamate receptors support a glutamate hypothesis of aggressive behavior. For example, mice deficient for the AMPA receptor GluR-A1 subunit are less aggressive than their wild-type counterparts (Vekovischeva et al., 2004) and treatment with AMPA receptor antagonists also reduces aggression in aggressive mice strains (Vekovischeva et al., 2007). Knockout of the GluA3-AMPA receptor subunit in mice is associated with a reduction in aggressive behavior (Adamczyk et al., 2012). In addition, genome-wide scans to identify aggression quantitative trait loci in aggressive mice strains find that the Gria3 gene, which encodes for a subunit of the AMPA3 receptor, accounts for the strain differences in aggressive behavior in the resident-intruder mouse model of aggression (Brodkin et al., 2002). Finally, selective mGlu-1 (Navarro et al., 2008) and mGlu-5 (Navarro et al., 2006), receptor blockade reduce aggression in mice models of aggression (Navarro et al., 2006). In contrast, agonist stimulation of auto-inhibitory mGlu-2/3 (Ago et al., 2012) or mGlu-7 (Navarro et al., 2009) receptors reduces aggression in mice.

Given the results of these various preclinical studies, we sought to explore if cerebrospinal fluid (CSF) Glutamate would be associated with aggression and/or impulsivity in personality disordered and healthy volunteer subjects. We hypothesized that CSF Glutamate would correlate directly with measures of aggression and/or impulsivity.

Section snippets

Subjects

Thirty-eight physically healthy subjects participated in this study. All subjects were medically healthy and were systematically evaluated in regard to aggressive and other behaviors as part of a larger program designed to study the biological correlates of impulsive aggressive and other personality-related behaviors. Subjects were recruited through public service announcements seeking out individuals who considered themselves to have difficulty managing their aggressive behaviors and,

Results

Demographic characteristics for the HV and PD subjects are displayed in Table 1. These groups did not differ in the distribution of gender or race or in age, height, weight, or in Hollinghead's socioeconomic score. However, multiple regression of raw CSF Glutamate levels, as dependent variable, and age, gender, race, SES, height and weight as independent variables, revealed a nearly significant relationship between raw CSF Glutamate levels and these demographic/physical variables (R = .56, R2

Discussion

This is the first study to investigate the relationship between central nervous system glutamate levels and aggression and/or impulsivity in human subjects. We found statistically significant direct correlations between CSF Glutamate levels and composite measures of aggression, impulsivity, and impulsive aggression in all subjects and in PD subjects. While this sample is modest in size, these results are consistent with the pre-clinical literature, and provide initial support for a

Conflict of interest statement

Dr. Coccaro reports being on the Scientific Advisory Board of Azevan Pharmaceuticals, Inc. and being a current recipient of grants from the NIMH. Dr. Lee reports being a past recipient of a research grant from Azevan Pharmaceuticals, Inc. Dr. Vezina reports no conflicts of interest regarding this work.

Role of funding source

This work was supported in part by grants from the National Institute of Mental Health: RO-1 MH46848 and RO-1 MH80109 (Dr. Coccaro) and R01 DA09397 (Dr. Vezina).

Acknowledgments

The authors thank Nancy Bubula and Margaret Wieczorek for their technical assistance in this work.

References (65)

  • E.F. Coccaro et al.

    Assessment of life history of aggression: development and psychometric characteristics

    Psychiatry Research

    (1997)
  • E.F. Coccaro et al.

    Cerebrospinal fluid substance p-like immunoreactivity correlates with aggression in personality disordered subjects

    Biological Psychiatry

    (2012)
  • E.F. Coccaro et al.

    Cerebrospinal fluid neuropeptide Y-like immunoreactivity correlates with impulsive aggression in human subjects

    Biological Psychiatry

    (2012)
  • G.E. Duncan et al.

    Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function

    Behaviorial Brain Research

    (2004)
  • W.O. Faustman et al.

    Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients

    Biological Psychiatry

    (1999)
  • M.A. Frye et al.

    Low cerebrospinal fluid glutamate and glycine in refractory affective disorder

    Biological Psychiatry

    (2007)
  • W.F. Gattaz et al.

    Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls

    Biological Psychiatry

    (1985)
  • E. Hrabovszky et al.

    Neurochemical characterization of hypothalamic neurons involved in attack behavior: glutamatergic dominance and co-expression of thyrotropin-releasing hormone in a subset of glutamatergic neurons

    Neuroscience

    (2005)
  • J.S. Kim et al.

    Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

    Neuroscience Letters

    (1980)
  • R. Lee et al.

    Cerebrospinal fluid oxytocin, life history of aggression, and personality disorder

    Psychoneuroendocrinology

    (2009)
  • C.H. Lin et al.

    Glutamate signaling in the pathophysiology and therapy of schizophrenia

    Pharmacology, Biochemistry, and Behavior

    (2012)
  • C.L. Lu et al.

    Role of NMDA receptors in hypothalamic facilitation of feline defensive rage elicited from the midbrain periaqueductal gray

    Brain Research

    (1992)
  • R. Machado-Vieira et al.

    Novel glutamatergic agents for major depressive disorder and bipolar disorder

    Pharmacology, Biochemistry, and Behavior

    (2012)
  • Y. Mirza et al.

    Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression

    Journal of the American Academy of Child and Adolescent Psychiatry

    (2004)
  • J.F. Navarro et al.

    Antiaggressive effects of MPEP, a selective antagonist of mGlu5 receptors, in agonistic interactions between male mice

    European Journal of Pharmacology

    (2006)
  • J.F. Navarro et al.

    JNJ16259685, a selective mGlu(1) antagonist, suppresses isolation-induced aggression in male mice

    European Journal of Pharmacology

    (2008)
  • M.J. Niciu et al.

    Overview of glutamatergic neurotransmission in the nervous system

    Pharmacology, Biochemistry, and Behavior

    (2012)
  • M.F. Olive et al.

    Glutamatergic medications for the treatment of drug and behavioral addictions

    Pharmacology, Biochemistry, and Behavior

    (2012)
  • T.L. Perry

    Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction

    Neuroscience Letters

    (1982)
  • B. Pfleiderer et al.

    Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients

    Psychiatry Research

    (2003)
  • C. Riaza Bermudo-Soriano et al.

    New perspectives in glutamate and anxiety

    Pharmacology, Biochemistry, and Behavior

    (2012)
  • D.R. Rosenberg et al.

    Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study

    Biological Psychiatry

    (2005)
  • Cited by (52)

    • Differences in aggression as psychiatric side effect of levetiracetam and perampanel in patients with epilepsy

      2022, Epilepsy and Behavior
      Citation Excerpt :

      The broad pharmacological effects of LEV make it difficult to determine the exact cause of aggression, though its modulating effects on AMPA receptors, 5-HT (serotonin), and GABA might be associated with aggression [14]. In contrast, PER acts as a highly selective noncompetitive antagonist toward AMPA receptors, thereby reducing glutamatergic transmission, while increased levels of glutamate are associated with increased aggressive behavior [24,25]. This selectivity for receptors shown with LEV and PER administrations may be associated with the differences in aggression between them found in the present subscale analysis.

    • The efficacy of perampanel in young children with drug-resistant epilepsy

      2020, Seizure
      Citation Excerpt :

      However, the most common adverse effects were similar to previous studies, including aggressive behavior, dizziness, and lethargy. The possible mechanism of aggressive behavior was discussed in the past, and the fluctuation of glutamate level in the brain, especially the amygdala, hypothalamus, and periaqueductal gray matter might play an important role [28]. The inhibiting effect of PER on glutamatergic transmission via the AMPA receptor may lead to this side effect [29].

    View all citing articles on Scopus
    View full text